Hypothesis

Chronic analgesic use blunts nociceptor‑driven calcium spikes that normally trigger a mild ROS burst, activating mitochondrial hormesis and downstream NAD+‑dependent repair pathways; suppressing this signal removes a recurrent rejuvenation cue, accelerating biological aging.

Mechanistic reasoning

• Nociceptor activation releases CGRP and substance P, which also stimulate TRPV1‑mediated calcium influx in sensory neurons and nearby non‑neuronal cells, causing a transient mitochondrial ROS increase that activates AMPK and SIRT1, promoting autophagy and senescent cell clearance.
• Analgesics (NSAIDs, acetaminophen, opioids) inhibit these pathways via COX inhibition, reduced prostaglandin sensitization, or μ‑opioid receptor signaling, dampening calcium flux and ROS hormesis 1.
• The frequency of minor injuries in daily life provides a quasi‑continuous hormetic stimulus; chronic analgesia converts this into a deficit akin to sedentary lifestyle, leading to epigenetic drift measurable by DNAm GrimAge.
• Moreover, pain‑evoked ATP release activates P2X7 receptors on macrophages, boosting NAD+ synthesis through CD38 inhibition; analgesic‑induced silence reduces this axis, lowering SIRT3 activity and mitochondrial deacetylation 2.

Testable predictions

1. In a longitudinal cohort of adults 40‑60 y, regular analgesic users (≥3 days/week for >6 months) will show higher GrimAge acceleration than matched low‑use controls, independent of baseline pain scores.
2. Circulating senescent‑associated secretory phenotype (SASP) factors (IL‑6, GDF15) and mitochondrial ROS biomarkers (8‑iso‑PGF2α) will be elevated in the analgesic group, reflecting impaired hormetic signaling.
3. A randomized, double‑blind crossover sub‑study giving analgesic users a low‑dose TRPV1 agonist (e.g., capsazepine 0.1 % cream) for 4 weeks will increase plasma 8‑iso‑PGF2α and reduce GrimAge change relative to placebo.

Falsifiability

• If analgesic users do not exhibit accelerated GrimAge or elevated SASP/ROS markers despite confirmed usage, the central claim that pain‑dependent hormesis contributes to aging is weakened.
• If TRPV1 agonist fails to shift ROS or epigenetic markers, the proposed nociceptor‑mitochondrial axis may be irrelevant in humans.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC8307464/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC6790390/